Lly stock price today

On 29 October 2026, Eli Lilly and Company saw its stock price experience downward pressure following the release of its third-quarter financial results. Despite maintaining a strong position in the pharmaceutical market, the company reported earnings that fell slightly short of aggressive Wall Street expectations, primarily due to increased manufacturing costs and supply chain investments aimed at scaling production for its high-demand metabolic drugs. Investors reacted cautiously to the updated guidance, which reflected the ongoing challenges of meeting global demand for its flagship weight-loss and diabetes treatments. While the company continues to report significant revenue growth driven by its core portfolio, the market remains sensitive to margin compression resulting from heavy capital expenditure. Analysts noted that while the long-term growth trajectory remains intact, the immediate stock performance reflects a period of consolidation as the company balances rapid expansion with operational efficiency. The share price movement on this date highlights the market's focus on near-term profitability metrics amidst the company's massive efforts to increase its global manufacturing footprint to address persistent supply constraints.